RARE: third_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/2810f22b-bc15-4f72-8eea-21b65c952978/","filing_uuid":"2810f22b-bc15-4f72-8eea-21b65c952978","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/2810f22b-bc15-4f72-8eea-21b65c952978/print/","filing_document_content_type":"text/html","income":"90000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jeffrey Miller","dt_posted":"2026-10-20T15:20:14-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"P.O. Box 625","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Buda","registrant_state":"TX","registrant_zip":"78610","registrant":{"id":401104313,"url":"https://lda.gov/api/v1/registrants/401104313/","house_registrant_id":null,"name":"MILLER STRATEGIES, LLC","description":"strategic public affairs","address_1":"P.O. Box 625","address_2":null,"address_3":null,"address_4":null,"city":"Buda","state":"TX","state_display":"Texas","zip":"78610","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JEFFREY MILLER","contact_telephone":"+1 202-434-8242","dt_updated":"2026-07-30T15:40:39.312430-04:00"},"client":{"id":72066,"url":"https://lda.gov/api/v1/clients/72066/","client_id":72066,"name":"ULTRAGENYX PHARMACEUTICAL INC.","general_description":"Biopharmaceutical company focused on developing novel therapies for rare genetic diseases","client_government_entity":null,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-03-01"},"lobbying_activities":[{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Issues relating to rare disease and patient access.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":65463,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69623,"prefix":null,"prefix_display":null,"first_name":"ASHLEY","nickname":null,"middle_name":null,"last_name":"GUNN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153052,"prefix":null,"prefix_display":null,"first_name":"NATALIE","nickname":null,"middle_name":null,"last_name":"MCINTYRE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}